Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rege

Showing results (981-990 of 1,003) with videos related to

Pageof 101
Sort By:
Leukemia Research|December 9, 2015
Dasatinib first-line: Multicentric Italian experience outside clinical trialsMassimo Breccia, Fabio Stagno, Luigiana Luciano, et al.
Oncotarget|November 21, 2017
The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemiaSara Galimberti, Cristina Bucelli, Elena Arrigoni, et al.
Molecular Pharmaceutics|December 16, 2024
Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop ReportChrister Tannergren, Sumit Arora, Andrew Babiskin, et al.
Hernia : the Journal of Hernias and Abdominal Wall Surgery|February 17, 2024
Delphi consensus statement for understanding and managing the subcostal hernia: subcostal hernias collaborative report (scholar study)S J Baig, G V Kulkarni, P Priya, et al.
Cancer Medicine|February 17, 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA studyMichele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, et al.
Drugs & Aging|May 18, 2013
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective studyRoberto Latagliata, Dario Ferrero, Alessandra Iurlo, et al.
Leukemia Research|July 23, 2014
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survivalMassimo Breccia, Luigiana Luciano, Roberto Latagliata, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
International Journal of Cardiology|March 17, 2022
Clinical characteristics and 30-day outcomes in patients with acute decompensated heart failure: Results from Indian College of Cardiology National Heart Failure Registry (ICCNHFR)P B Jayagopal, Sridhar L Sastry, Veena Nanjappa, et al.
Cancer Research|May 2, 2023
β-Catenin-Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal CancerDipika R Mohan, Kleiton S Borges, Isabella Finco, et al.
Pageof 101

Showing results (981-990 of 1,003) with videos related to

Sort By:
Pageof 101
Leukemia Research|December 9, 2015
Dasatinib first-line: Multicentric Italian experience outside clinical trialsMassimo Breccia, Fabio Stagno, Luigiana Luciano, et al.
Oncotarget|November 21, 2017
The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemiaSara Galimberti, Cristina Bucelli, Elena Arrigoni, et al.
Molecular Pharmaceutics|December 16, 2024
Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop ReportChrister Tannergren, Sumit Arora, Andrew Babiskin, et al.
Hernia : the Journal of Hernias and Abdominal Wall Surgery|February 17, 2024
Delphi consensus statement for understanding and managing the subcostal hernia: subcostal hernias collaborative report (scholar study)S J Baig, G V Kulkarni, P Priya, et al.
Cancer Medicine|February 17, 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA studyMichele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, et al.
Drugs & Aging|May 18, 2013
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective studyRoberto Latagliata, Dario Ferrero, Alessandra Iurlo, et al.
Leukemia Research|July 23, 2014
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survivalMassimo Breccia, Luigiana Luciano, Roberto Latagliata, et al.
Frontiers in Pharmacology|April 10, 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life studyA Iurlo, D Cattaneo, D Consonni, et al.
International Journal of Cardiology|March 17, 2022
Clinical characteristics and 30-day outcomes in patients with acute decompensated heart failure: Results from Indian College of Cardiology National Heart Failure Registry (ICCNHFR)P B Jayagopal, Sridhar L Sastry, Veena Nanjappa, et al.
Cancer Research|May 2, 2023
β-Catenin-Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal CancerDipika R Mohan, Kleiton S Borges, Isabella Finco, et al.
Pageof 101